PUBLISHER: Bizwit Research & Consulting LLP | PRODUCT CODE: 1755706
PUBLISHER: Bizwit Research & Consulting LLP | PRODUCT CODE: 1755706
The Global Shikimic Acid Market is valued approximately at USD 8.04 billion in 2024 and is projected to expand at a compound annual growth rate (CAGR) of 4.73% over the forecast period from 2025 to 2035. Shikimic acid, a cyclohexene, is a pivotal biochemical intermediate in the biosynthesis of aromatic amino acids and other phenolic compounds. Its importance in pharmaceutical formulations, particularly in the production of antiviral drugs like oseltamivir (Tamiflu), is driving its surging commercial demand. Furthermore, its role as a precursor in manufacturing various cosmetic and food-grade compounds continues to catalyze cross-industry adoption. Increasing focus on plant-derived and sustainable chemical synthesis, combined with advancements in fermentation and extraction technologies, is further uplifting the market trajectory.
Driven by an escalating requirement for safe and effective pharmaceutical intermediates, the demand for shikimic acid has witnessed substantial growth, particularly from the healthcare and cosmetic sectors. The pharmaceutical-grade variant dominates the global consumption landscape, especially with the intensifying preparedness for influenza pandemics and emerging infectious diseases. Concurrently, rising awareness about organic food additives and clean-label beauty products is fueling its application in food-grade and cosmetic-grade formulations. However, the high cost associated with plant-based extraction and the limited availability of raw materials such as star anise can create bottlenecks in mass production, spurring the need for cost-efficient synthetic biology and fermentation-based alternatives.
Regionally, Asia Pacific is projected to command the largest and fastest-growing share of the shikimic acid market, driven by the abundance of natural sources in China and India, as well as rapidly expanding pharmaceutical and cosmetic manufacturing bases. China's dominance in star anise cultivation grants it a unique upstream advantage, enabling efficient large-scale extraction. North America, particularly the U.S., continues to be a leading consumer, propelled by innovation in drug development and robust investment in biotechnological research. Meanwhile, Europe remains a stable yet moderately growing market, constrained by regulatory pressures and supply-chain sensitivity. Latin America and the Middle East & Africa are gradually emerging due to improving access to bio-based pharmaceutical ingredients and an increasing footprint of global cosmetics brands.
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values for the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within the countries involved in the study. The report also provides detailed information about crucial aspects, such as driving factors and challenges, which will define the future growth of the market. Additionally, it incorporates potential opportunities in micro-markets for stakeholders to invest, along with a detailed analysis of the competitive landscape and product offerings of key players. The detailed segments and sub-segments of the market are explained below: